OrbiMed Genesis GP LLC — SEC insider filings
SEC reporting owner CIK 1808744. 91 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers the 50 most recent of 91 filings on record, filed 2023-05-08 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 59 legs across 19 filings — 29,200,648 shares, $162,291,019 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 79 legs across 19 filings — 9,996,869 shares, $175,868,866 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 65.
- Largest priced transaction: sale of 787,024 shares @ $45.38 ($35,715,149) in Enliven Therapeutics, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 4 | — | 8 legs · 2,174,831 sh · $74,560,296 | 2 |
| Disc Medicine, Inc. (IRON) | Director | 7 | 3 legs · 83,334 sh · $3,000,024 | 39 legs · 939,675 sh · $52,696,562 | 2 |
| Braveheart Bio, Inc. (BRVE) | Director, 10% owner | 1 | 2 legs · 1,940,000 sh · $34,920,000 | — | 2 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) | Director | 3 | — | 6 legs · 1,546,347 sh · $28,671,734 | 4 |
| Electra Therapeutics, Inc. (ETRA) | Director, 10% owner | 3 | 18 legs · 1,898,020 sh · $24,349,642 | — | 8 |
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, 10% owner | 1 | 3 legs · 950,000 sh · $16,150,000 | — | 16 |
| Adicet Bio, Inc. (ACET) | 10% owner | 4 | 9 legs · 9,000,000 sh · $14,328,750 | 4 legs · 104,658 sh · $674,847 | — |
| Q32 Bio Inc. (QTTB) | Director, 10% owner | 1 | 2 legs · 1,875,000 sh · $15,000,000 | — | — |
| Edgewise Therapeutics, Inc. (EWTX) | Director, 10% owner | 2 | 3 legs · 951,316 sh · $14,999,995 | — | — |
| MBX Biosciences, Inc. (MBX) | Director, 10% owner | 2 | 6 legs · 940,672 sh · $14,020,756 | — | 5 |
+11 more issuers among the filings shown — every filing appears in the table below.
Insider filings — OrbiMed Genesis GP LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Purchase (P): 9,816 @ $7.85 · Purchase (P): 39,600 @ $7.85 · Purchase (P): 4,000 @ $8.24 · Purchase (P): 16,000 @ $8.24 · Purchase (P): 20,700 @ $8.45 · Purchase (P): 2,000 @ $8.45 | EDGAR |
| 2026-11-05 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Purchase (P): 24,313 @ $7.84 · Purchase (P): 97,800 @ $7.84 · Purchase (P): 24,400 @ $7.88 · Purchase (P): 98,600 @ $7.88 · Purchase (P): 9,267 @ $7.78 · Purchase (P): 37,100 @ $7.78 · +4 more | EDGAR |
| 2026-09-30 | 4 | ADARx Pharmaceuticals, Inc. (ADRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Conversion (C): 10,690,530 · Conversion (C): 2,000,962 · Conversion (C): 769,601 · Conversion (C): 564,187 · Purchase (P): 300,249 @ $17 · Conversion (C): 7,127,019 · +13 more | EDGAR |
| 2026-09-23 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Conversion (C): 2,002,310 · Conversion (C): 1,087,934 · Conversion (C): 1,703,314 · Purchase (P): 333,333 @ $15 · Conversion (C): 758,279 · Purchase (P): 1,000,000 @ $15 · +4 more | EDGAR |
| 2026-08-11 | 4 | Braveheart Bio, Inc. (BRVE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Sale (S): 24,846 @ $45.38 · Sale (S): 1,477 @ $45 · Sale (S): 787,024 @ $45.38 · Sale (S): 46,776 @ $45 | EDGAR |
| 2026-06-17 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Sale (S): 9,086 @ $45.02 · Sale (S): 272,322 @ $45.02 | EDGAR |
| 2026-06-15 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC | Purchase (P): 1,041,667 (derivative) · Purchase (P): 208,333 (derivative) | EDGAR |
| 2026-06-09 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC | Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) · Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) | EDGAR |
| 2026-06-01 | 4 | Q32 Bio Inc. (QTTB) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-04-23 | 4 | Prelude Therapeutics Inc (PRLD) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, ORBIMED CAPITAL LLC | Purchase (P): 1,689,189 @ $4.44 · Purchase (P): 1,126,126 @ $4.44 | EDGAR |
| 2026-04-16 | 4 | ImageneBio, Inc. (IMA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Purchase (P): 336,603 (derivative) · Purchase (P): 384,689 (derivative) | EDGAR |
| 2026-04-09 | 4 | Adicet Bio, Inc. (ACET) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Sale (S): 29,319 @ $6.53 · Sale (S): 2,400 @ $6.38 · Sale (S): 32,523 @ $6.29 · Sale (S): 40,416 @ $6.52 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-10-10 | 4 | Adicet Bio, Inc. (ACET) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Purchase (P): 1,500,000 @ $1 · Purchase (P): 3,500,000 @ $1 | EDGAR |
| 2025-09-02 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC | Purchase (P): 5,255,106 @ $0.87 · Purchase (P): 1,051,021 @ $0.87 · Purchase (P): 10,111,384 (derivative) · Purchase (P): 2,022,277 (derivative) · Purchase (P): 15,366,490 (derivative) · Purchase (P): 3,073,298 (derivative) | EDGAR |
| 2025-07-30 | 4 | ImageneBio, Inc. (IKNA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Grant/award (A): 83,611 @ $2.49 | EDGAR |
| 2025-04-11 | 4 | Compass Therapeutics, Inc. (CMPX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-04-04 | 4 | Edgewise Therapeutics, Inc. (EWTX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Purchase (P): 372,578 @ $20.13 · Purchase (P): 124,193 @ $20.13 | EDGAR |
| 2025-03-26 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Sale (S): 1,956 @ $54.11 · Sale (S): 3,026 @ $54.11 · Sale (S): 756 @ $54.11 | EDGAR |
| 2025-03-21 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Sale (S): 13,517 @ $54.02 · Sale (S): 20,911 @ $54.02 · Sale (S): 5,228 @ $54.02 · Sale (S): 941 @ $54.01 · Sale (S): 1,457 @ $54.01 · Sale (S): 364 @ $54.01 · +3 more | EDGAR |
| 2025-03-12 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Sale (S): 68,766 @ $54.29 · Sale (S): 106,384 @ $54.29 · Sale (S): 26,596 @ $54.29 · Sale (S): 136 @ $55.01 · Sale (S): 211 @ $55.01 · Sale (S): 53 @ $55.01 · +9 more | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-08-15 | 4 | scPharmaceuticals Inc. (SCPH) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Purchase (P): 478,342 @ $4 · Purchase (P): 21,658 @ $4 | EDGAR |
| 2024-08-15 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Sale (S): 220,600 @ $44.01 · Sale (S): 29,400 @ $44.01 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Ltd | Sale (S): 39,433 @ $10 · Sale (S): 5,401 @ $10 · Sale (S): 6,142 @ $10 · Sale (S): 4,009 @ $10 · Sale (S): 556 @ $10 · Sale (S): 623 @ $10 | EDGAR |
| 2024-06-20 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Purchase (P): 28,404 @ $36 · Purchase (P): 43,944 @ $36 · Purchase (P): 10,986 @ $36 | EDGAR |
| 2024-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Sale (S): 33,300 @ $22.14 · Sale (S): 1,000,000 @ $22.14 | EDGAR |
| 2024-05-20 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Code (U): 2,416,181 · Code (U): 264,315 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, ORBIMED CAPITAL LLC | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Code (U): 17,063,000 · Code (U): 650,600 | EDGAR |
| 2024-01-26 | 4 | Adicet Bio, Inc. (ACET) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Purchase (P): 1,841,100 @ $2.40 · Purchase (P): 242,200 @ $2.40 · Purchase (P): 1,041,700 @ $2.40 | EDGAR |
| 2024-01-25 | 4 | Edgewise Therapeutics, Inc. (EWTX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Purchase (P): 454,545 @ $11 | EDGAR |
| 2024-01-16 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Option exercise/expiry (X): 145,251 @ $12.74 · Option exercise/expiry (X): 145,251 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Sale (S): 162,576 @ $19.96 · Sale (S): 18,922 @ $19.96 · Sale (S): 26,872 @ $19.82 · Sale (S): 3,128 @ $19.82 · Sale (S): 1,195,683 @ $18.32 · Sale (S): 139,166 @ $18.32 | EDGAR |
| 2023-12-20 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Option exercise (M): 1,724 @ $38 · Sale (S): 1,724 @ $59.24 · Option exercise (M): 1,724 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Sale (S): 228,500 @ $56.75 · Sale (S): 147,600 @ $56.75 · Sale (S): 57,100 @ $56.75 | EDGAR |
| 2023-12-14 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC | Sale (S): 14,400 @ $60.16 · Sale (S): 9,300 @ $60.16 · Sale (S): 3,600 @ $60.16 · Sale (S): 56,200 @ $58.56 · Sale (S): 36,400 @ $58.56 · Sale (S): 14,100 @ $58.56 · +2 more | EDGAR |
| 2023-11-24 | 4 | PMV Pharmaceuticals, Inc. (PMVP) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC | Sale (S): 87,786 @ $2.23 | EDGAR |
| 2023-09-21 | 4/A | Ikena Oncology, Inc. (IKNA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-09-14 | 4 | Ikena Oncology, Inc. (IKNA) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-08-17 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd, OrbiMed Capital GP VII LLC | Sale (S): 38,327 @ $0.75 · Sale (S): 248,819 @ $0.75 · Sale (S): 535,534 @ $0.75 | EDGAR |
| 2023-08-02 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd, OrbiMed Capital GP VII LLC | Sale (S): 26,622 @ $3 · Sale (S): 29,700 @ $3 · Sale (S): 153,078 @ $3 | EDGAR |
| 2023-07-27 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd, OrbiMed Capital GP VII LLC | Sale (S): 7,800 @ $2.92 · Sale (S): 4,700 @ $2.92 · Sale (S): 26,700 @ $2.92 | EDGAR |
| 2023-07-19 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Purchase (P): 328,482 @ $3.05 · Purchase (P): 151,450 @ $3.05 | EDGAR |
| 2023-07-17 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd, OrbiMed Capital GP VII LLC | Sale (S): 9,800 @ $2.40 · Sale (S): 52,800 @ $2.40 · Sale (S): 132,100 @ $2.40 | EDGAR |
| 2023-06-29 | 4 | Adicet Bio, Inc. (ACET) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership, Chimovits Erez | Purchase (P): 125,000 @ $2.09 · Purchase (P): 250,000 @ $2.09 · Purchase (P): 442,000 @ $2.09 · Purchase (P): 58,000 @ $2.09 | EDGAR |
| 2023-05-19 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC | Option exercise (M): 2,125 @ $4.28 · Option exercise (M): 2,125 (derivative) @ $0 | EDGAR |
| 2023-05-08 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, ORBIMED CAPITAL LLC | Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1808744 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs